FDA's on­col­o­gy ad­comm to re­view PI3K in­hibitors in blood can­cers in April

An at­trac­tive can­cer tar­get is go­ing to be in the hot seat at an FDA ad­vi­so­ry com­mit­tee on April 21.

The FDA’s on­co­log­ic drugs ad­vi­so­ry com­mit­tee, or ODAC, will specif­i­cal­ly dis­cuss a par­tic­u­lar class of can­cer drugs, known as phos­phatidyli­nos­i­tol-3-ki­nase, or PI3K, in­hibitors, that are cur­rent­ly un­der de­vel­op­ment in pa­tients with hema­to­log­ic ma­lig­nan­cies, or blood can­cers.

The out­side ad­vi­sors will dis­cuss whether ran­dom­ized da­ta should be re­quired to sup­port a demon­stra­tion of sub­stan­tial ev­i­dence of ef­fec­tive­ness and that the drug is safe for its in­tend­ed use.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER